variables: 817014
Data license: CC-BY
This data as json
id | name | unit | description | createdAt | updatedAt | code | coverage | timespan | datasetId | sourceId | shortUnit | display | columnOrder | originalMetadata | grapherConfigAdmin | shortName | catalogPath | dimensions | schemaVersion | processingLevel | processingLog | titlePublic | titleVariant | attributionShort | attribution | descriptionShort | descriptionFromProducer | descriptionKey | descriptionProcessing | licenses | license | grapherConfigETL | type | sort | dataChecksum | metadataChecksum |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
817014 | Bacteriologically confirmed pulmonary tuberculosis patients with rifampicin resistance and resistance to second-line injectable agents | patients | 2023-12-05 11:52:02 | 2024-07-25 22:54:12 | 2017-2018 | 6308 | { "unit": "patients", "numDecimalPlaces": 0 } |
0 | rr_dr_2li | grapher/tuberculosis/2023-11-27/drug_resistance_surveillance/drug_resistance_surveillance#rr_dr_2li | 2 | major | Number of bacteriologically confirmed pulmonary tuberculosis patients with rifampicin resistance and resistance to second-line injectable agents. Rifampicin resistance is the ability of tuberculosis bacteria, to resist the effects of the antibiotic rifampicin due to genetic mutations, hindering the drug's ability to inhibit bacterial growth. Fluoroquinolones and other second-line injectable agents are antibiotics used to treat tuberculosis after first-line drugs such as rifampicin are no longer effective. | Number of new or previously treated bacteriologically confirmed pulmonary tuberculosis patients with resistance to rifampicin and resistance to second-line injectable agents | [] |
int | [] |
3d2db019db46a20e779c274bf39963c1 | ced9e623db5ed082fe7ae71091163640 |